🟢 GlaxoSmithKline is trading 4.17% up in pre-market after Ris-Rez reduced death risk 54% versus topotecan

GlaxoSmithKline is trading 4.17% up at $50.14 after positive Phase III Ris-Rez data reduced the risk of death by 54% versus topotecan in relapsed small-cell lung cancer.

• Ris-Rez patients had median overall survival of 18.5 months versus 10.3 months with chemotherapy.
• The company-specific catalyst is outweighing the broader risk-off pre-market environment, with major U.S. indexes lower on September 14, 2026.